Novavax

company

About

Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$175.25M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 1987
Number Of Employee
1001 - 5000
Operating Status
Active
Stock Symbol
nasdaq:NVAX
Legal Name
Novavax AB
Also Known As
Isconova,Molecular Packaging Systems

Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
10
$2.62B
Novavax has raised a total of $2.62B in funding over 2 rounds. Their latest funding was raised on Dec 15, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 15, 2022 Post-IPO Equity $74.75M Detail
Dec 14, 2022 Post-IPO Debt $175.25M Detail
Jul 7, 2020 Grant $1.60B 1 Government of United States of America Detail
Jun 15, 2020 Post-IPO Equity $200M 1 RA Capital Management Detail
May 11, 2020 Grant $384M 1 Coalition for Epidemic Preparedness Innovations Detail

Investors

Number of Lead Investors
Number of Investors
4
5
Novavax is funded by 5 investors. Government of United States of America and RA Capital Management are the most recent investors.
Investor Name Lead Investor Funding Round
Government of United States of America Yes Grant
RA Capital Management Yes Post-IPO Equity
Coalition for Epidemic Preparedness Innovations Yes Grant
Bill & Melinda Gates Foundation Grant
Innovations Kapital Post-IPO Equity

Employee Profiles

Number of Employee Profiles
21
Novavax has 21 current employee profiles, including Executive Bobby Lodin
Executive
Board member
Executive
Executive
Executive

Acquisition

Novavax has acquired 1 organizations. Their most recent acquisition was Isconova AB on Dec 2, 2013. They acquired Isconova AB for 0.

Date Company Name
Industry Acquisition Type Price
Dec 2, 2013 Isconova AB
Biotechnology acquisition Detail